Cover Image

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi
  • Aikaterini Kyriakou
    Second Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, General Hospital “Papageorgiou”, Greece | docmouli@gmail.com
  • Anastasia Trigoni
    Second Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, General Hospital “Papageorgiou”, Greece
  • Nikiforos Galanis
    Division of Sports Medicine, Department of Orthopedics, Medical School, Aristotle University of Thessaloniki, Greece
  • Dimitrios Sotiriadis
    Second Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, General Hospital “Papageorgiou”, Greece
  • Aikaterini Patsatsi
    Second Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, General Hospital “Papageorgiou”, Greece

Abstract

Hidradenitis suppurativa (HS) is a relapsing, inflammatory disease characterized by painful nodules, abscesses, sinuses track formation and scarring. HS has a great impact on patients’ quality of life and its treatment may be really challenging. Adalimumab provides a new therapeutic option for HS. Our aim was to assess the therapeutic potential of adalimumab on patients with HS based on the data from the daily clinical practice of an HS Outpatient Clinic. 19 patients with clinically evident moderate to severe HS, under adalimumab treatment for at least 24 week, participated in this observational, retrospective study. The Hidradenitis Suppurativa Physician’s Global Assessment scale, Modified Santorius scale and Dermatology Life Quality Index (DLQI) at baseline, week 4, week 12 and week 24 were retrieved from the records. Both Modified Santorius score and DLQI were significantly decreased during the weeks of evaluation (Friedman’s test; P < 0.001). The proportion of patients who achieved clinical response was 10.5% (n = 2) at week 4, 42.1% (n = 8) at week 12 and 63.2% (n = 12) at week 24. Treatment with adalimumab was linked with both clinical remission of HS and improvement of patients’ quality of life.

Keywords

Adalimumab; Hidradenitis suppurativa; Acne inversa

Full Text:

PDF
Submitted: 2018-08-31 10:02:10
Published: 2018-10-01 12:12:45
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
32

Views:
PDF
2

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy